Was the ResMed (RMD) director’s share sale under a Rule 10b5-1 plan?

Yes. A footnote states the transaction was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025. Such plans pre-schedule trades, indicating this 2,000-share sale at $225.00 was part of an established program.

ResMed (NYSE: RMD) director sells 2,000 shares under Rule 10b5-1 plan

Q: Who is the ResMed (RMD) insider involved in the reported share sale?

The transaction involves Peter C. Farrell, a director of ResMed Inc. He executed an open-market sale of 2,000 ResMed Common Stock shares at $225.00 per share and now directly owns 60,773 shares after the transaction, according to the Form 4.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

ResMed Inc. director Peter C. Farrell reported an open-market sale of 2,000 shares of ResMed Common Stock at $225.00 per share. After this transaction, he directly holds 60,773 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 2,000 shares ($450,000)

Net Sell 1 txn

Insider FARRELL PETER C

Role Director

Sold 2,000 shs ($450K)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock	2,000	$225.00	$450K

Holdings After Transaction: ResMed Common Stock — 60,773 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 2,000 shares Sale price per share: $225.00 per share Shares owned after transaction: 60,773 shares +2 more

5 metrics

Shares sold 2,000 shares Open-market sale of ResMed Common Stock

Sale price per share $225.00 per share Price for the 2,000-share open-market sale

Shares owned after transaction 60,773 shares Direct holdings after the reported sale

Transaction code S Sale in open market or private transaction

Trading plan reference Rule 10b5-1 plan Plan adopted August 12, 2025 for scheduled trades

Key Terms

Open-market sale, Rule 10b5-1 plan, Form 4

3 terms

Open-market sale financial

"classified as an open-market sale of 2,000 shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Rule 10b5-1 plan regulatory

"transaction was conducted under a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Form 4 regulatory

"reported in a Form 4 insider transaction filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/02/2026 - 01:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FARRELL PETER C

(Last)

(First)

(Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO

CALIFORNIA

92123

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock	04/01/2026		S⁽¹⁾		2,000	D	$225	60,773	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

	/s/ Peter C. Farrell, Chairman emeritus	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ResMed (RMD) disclose in this Form 4?

ResMed reported that director Peter C. Farrell completed an open-market sale of 2,000 shares of ResMed Common Stock at $225.00 per share. Following the trade, he directly holds 60,773 shares, as reflected in the filing’s ownership table.

How many ResMed (RMD) shares did the director sell and at what price?

Director Peter C. Farrell sold 2,000 shares of ResMed Common Stock at a price of $225.00 per share. The transaction is classified as an open-market sale, and his direct ownership after the trade is reported as 60,773 shares in total.

How many ResMed (RMD) shares does Peter C. Farrell hold after the sale?

After the reported transaction, Peter C. Farrell directly owns 60,773 shares of ResMed Common Stock. This reflects his position after selling 2,000 shares at $225.00 per share in an open-market sale recorded in the Form 4 filing.

Is the reported ResMed (RMD) transaction a buy or a sell?

The filing shows a sale. Director Peter C. Farrell executed an open-market sale of 2,000 ResMed Common Stock shares at $225.00 per share, coded as an “S” transaction, and now directly holds 60,773 shares following this disposition.